107 related articles for article (PubMed ID: 25671541)
1. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.
Goldmacher VS; Audette CA; Guan Y; Sidhom EH; Shah JV; Whiteman KR; Kovtun YV
PLoS One; 2015; 10(2):e0117523. PubMed ID: 25671541
[TBL] [Abstract][Full Text] [Related]
2. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
3. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Oroudjev E; Lopus M; Wilson L; Audette C; Provenzano C; Erickson H; Kovtun Y; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2700-13. PubMed ID: 20937595
[TBL] [Abstract][Full Text] [Related]
4. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
5. Antitubulin activities of ansamitocins and maytansinoids.
Ikeyama S; Takeuchi M
Biochem Pharmacol; 1981 Sep; 30(17):2421-5. PubMed ID: 21043240
[TBL] [Abstract][Full Text] [Related]
6. C3 ester side chain plays a pivotal role in the antitumor activity of Maytansinoids.
Li W; Huang M; Li Y; Xia A; Tan L; Zhang Z; Wang Y; Yang J
Biochem Biophys Res Commun; 2021 Aug; 566():197-203. PubMed ID: 34144258
[TBL] [Abstract][Full Text] [Related]
7. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Sun X; Widdison W; Mayo M; Wilhelm S; Leece B; Chari R; Singh R; Erickson H
Bioconjug Chem; 2011 Apr; 22(4):728-35. PubMed ID: 21391620
[TBL] [Abstract][Full Text] [Related]
8. Modeling the effects of drug binding on the dynamic instability of microtubules.
Hinow P; Rezania V; Lopus M; Jordan MA; Tuszyński JA
Phys Biol; 2011 Oct; 8(5):056004. PubMed ID: 21836336
[TBL] [Abstract][Full Text] [Related]
9. Antibody-DM1 conjugates as cancer therapeutics.
Lopus M
Cancer Lett; 2011 Aug; 307(2):113-8. PubMed ID: 21481526
[TBL] [Abstract][Full Text] [Related]
10. Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes.
Fishkin N
Mol Pharm; 2015 Jun; 12(6):1745-51. PubMed ID: 25738231
[TBL] [Abstract][Full Text] [Related]
11. Maytansinol Functionalization: Towards Useful Probes for Studying Microtubule Dynamics.
Boiarska Z; Pérez-Peña H; Abel AC; Marzullo P; Álvarez-Bernad B; Bonato F; Santini B; Horvath D; Lucena-Agell D; Vasile F; Sironi M; Díaz JF; Prota AE; Pieraccini S; Passarella D
Chemistry; 2023 Jan; 29(5):e202203431. PubMed ID: 36468686
[TBL] [Abstract][Full Text] [Related]
12. Binding of maytansinoids to tubulin.
York J; Wolpert-DeFilippes MK; Johns DG; Sethi VS
Biochem Pharmacol; 1981 Dec; 30(23):3239-43. PubMed ID: 7317106
[No Abstract] [Full Text] [Related]
13. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
14. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
[TBL] [Abstract][Full Text] [Related]
15. Interaction of 4-arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin.
Rappl C; Barbier P; Bourgarel-Rey V; Grégoire C; Gilli R; Carre M; Combes S; Finet JP; Peyrot V
Biochemistry; 2006 Aug; 45(30):9210-8. PubMed ID: 16866367
[TBL] [Abstract][Full Text] [Related]
16. Linkages in tubulin-colchicine functions: the role of the ring C (C') oxygens and ring B in the controls.
Pérez-Ramírez B; Gorbunoff MJ; Timasheff SN
Biochemistry; 1998 Feb; 37(6):1646-61. PubMed ID: 9484236
[TBL] [Abstract][Full Text] [Related]
17. Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site.
Venghateri JB; Gupta TK; Verma PJ; Kunwar A; Panda D
PLoS One; 2013; 8(10):e75182. PubMed ID: 24124473
[TBL] [Abstract][Full Text] [Related]
18. A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma.
Porter J; Ding Y; Hale SJM; Perrins RD; Robinson A; Mazanetz MP; Wu Y; Ma Y; Conlon K; Coulter T
Bioorg Med Chem Lett; 2020 Dec; 30(24):127634. PubMed ID: 33148516
[TBL] [Abstract][Full Text] [Related]
19. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
20. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
